Status:
COMPLETED
Inhaled Sedation in COVID-19-related Acute Respiratory Distress Syndrome (ISCA): an International Research Data Study in the Recent Context of Widespread Disease Resulting From the 2019 (SARS-CoV2) Coronavirus Pandemics (COVID-19)
Lead Sponsor:
University Hospital, Clermont-Ferrand
Collaborating Sponsors:
Hospital Clínico Universitario de Valencia
University Hospital Schleswig-Holstein
Conditions:
Critically Illness
Sedation
Eligibility:
All Genders
18+ years
Brief Summary
The authors hypothesized that inhaled sedation, either with isoflurane or sevoflurane, might be associated with improved clinical outcomes in patients with COVID-19-related ARDS, compared to intraveno...
Detailed Description
The acute respiratory distress syndrome (ARDS) is the most severe and lethal complication of COVID-19, and healthcare resource utilizations are currently being heavily challenged in most countries wor...
Eligibility Criteria
Inclusion
- Adult patients (18 years old),
- Admitted to a participating ICU (or any other ICU-like setting that may be deployed as a result of the COVID-19 pandemics, such as in the operating room, post-anesthesia care unit, step-down unit or any COVID-19-specific unit set in response to the pandemics in a participating center),
- Requiring invasive mechanical ventilation,
- With suspected or confirmed COVID-19 on day 0.
Exclusion
- None
Key Trial Info
Start Date :
June 26 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 30 2021
Estimated Enrollment :
203 Patients enrolled
Trial Details
Trial ID
NCT04383730
Start Date
June 26 2020
End Date
April 30 2021
Last Update
September 5 2021
Active Locations (12)
Enter a location and click search to find clinical trials sorted by distance.
1
Beth Israel Deaconess Medical Center, Inc.
Boston, Massachusetts, United States, 02215
2
CHU
Brest, France
3
CHU
Clermont-Ferrand, France, 63000
4
Centre Hospitalier
Dunkirk, France